Please Remove Adblock
Adverts are the main source of Revenue for DoveMed. Please remove adblock to help us create the best medical content found on the Internet.

Molecular Testing for Epithelioid Hemangioendothelioma

Last updated March 2, 2017

Molecular Testing for Epithelioid Hemangioendothelioma is a genetic test that is helpful in confirming a diagnosis of epithelioid hemangioendothelioma.

What are other Names for this Test? (Equivalent Terms)

  • Gene Mutation Analysis for Epithelioid Hemangioendothelioma
  • Molecular Testing for Epithelioid Haemangioendothelioma
  • Test for Molecular Diagnosis of Epithelioid Hemangioendothelioma

What is Molecular Testing for Epithelioid Hemangioendothelioma? (Background Information)

  • Molecular Testing for Epithelioid Hemangioendothelioma is a genetic test that is helpful in confirming a diagnosis of epithelioid hemangioendothelioma. It is also subsequently useful in taking treatment decisions
  • Epithelioid hemangioendothelioma (EHE) is a tumor involving the blood vessels and surrounding epithelioid cells. The blood vessels are lined by epithelioid cells, which grow abnormally to form the tumor
  • A majority of the tumors behave in a benign manner; however, these tumors have a malignancy potential (capacity to metastasize). EHE frequently affects the soft tissues, just below the skin (subcutaneous tissue). It can also occur deep inside the body organs
  • This tumor has been observed in the liver, lungs, limbs, bones, and on the skin. Teenagers and young adults are most commonly affected by EHE

The cause of epithelioid hemangioendothelioma is due to genetic mutations. Currently, studies indicate defects in the following genes:

  • WWTR1-CAMTA1 causing chromosomal translocation abnormality namely t(1;3)(p36;q25)
  • TFE3-YAP1 causing chromosomal translocation abnormality namely t(X;11)(p11.2;q22.1)

The above genetic abnormalities can be detected using molecular studies, which may play a significant role in identifying the tumor type, and in some cases, helping the healthcare provider take appropriate treatment decisions.

The molecular testing, in general, can be performed using a variety of methods. Some of these methods include:

  • In situ hybridization technique, such as fluorescence in situ hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Next-generation sequencing (NGS)
  • Polymerase chain reaction (PCR)
  • Comparative genomic hybridization (CGH)
  • Karyotyping including spectral karyotyping
  • mRNA analysis
  • Tissue microarrays (TMAs)
  • Southern blot test
  • Northern blot test
  • Western blot test
  • Eastern blot test

The methodology used for epithelioid hemangioendothelioma may vary from one laboratory to another. 

Note: Molecular testing has limitations due to the molecular method and genetic mutational abnormalities being tested. This can affect the results on a case-by-case basis. Consultation with your healthcare provider will help in determining the right test and right molecular method, based on individual circumstances.

What are the Clinical Indications for performing the Molecular Testing for Epithelioid Hemangioendothelioma Test?

Molecular Testing for Epithelioid Hemangioendothelioma is undertaken in the following situations: 

  • To assist (and in some cases, confirm) the initial diagnosis of epithelioid hemangioendothelioma
  • To distinguish other tumors/conditions that have similar histological features, when examined by a pathologist under the microscope
  • To help in determining treatment options
  • To confirm recurrence of the tumor: Tumor recurrence can either be at the original tumor site, or at a distant location (away from the initial site)

How is the Specimen Collected for Molecular Testing for Epithelioid Hemangioendothelioma?

Following is the specimen collection process for Molecular Testing for Epithelioid Hemangioendothelioma:

The specimen sample requirements may vary from lab to lab. Hence, it is important to contact the testing lab for exact specimen requirements, before initiating the testing process.

  • Sample required:
    • Fresh tumor tissue during biopsy
    • Formalin-fixed paraffin-embedded solid tumor tissue (FFPE tumor tissue), often referred to as paraffin block of the tumor
    • Unstained tissue slides
  • Process of obtaining the sample: As outlined by the laboratory testing facility
  • Preparation required: As outlined by the laboratory testing facility


  • Depending on the location of testing, it may take up to 2 weeks’ turnaround time, to obtain the test results
  • Occasionally, additional samples may be required to either repeat the test or to perform follow-up testing
  • Many hospitals preserve the paraffin blocks for at least 7 years. In general, older paraffin blocks (over 5 years) may affect the detection of specific mutations, due to degradation of the tumor specimen over time

Cost of Molecular Testing for Epithelioid Hemangioendothelioma:

  • The cost of the test procedure depends on a variety of factors, such as the type of your health insurance, annual deductibles, co-pay requirements, out-of-network and in-network of your healthcare providers and healthcare facilities
  • In many cases, an estimate may be provided before the test is conducted. The final amount may depend upon the findings during the test procedure and post-operative care that is necessary (if any)

What is the Significance of the Molecular Testing for Epithelioid Hemangioendothelioma Result?

The significance of Molecular Testing for Epithelioid Hemangioendothelioma is explained:

  • Presence of a positive test result helps aid, and in some cases, confirm the diagnosis of epithelioid hemangioendothelioma
  • The result can help exclude other tumors with similar histological features
  • It can help determine the prognosis of the patient
  • In some cases, the test results may help in taking treatment decisions

The laboratory test results are NOT to be interpreted as results of a "stand-alone" test. The test results have to be interpreted after correlating with suitable clinical findings and additional supplemental tests/information. Your healthcare providers will explain the meaning of your tests results, based on the overall clinical scenario.

Additional and Relevant Useful Information:

  • Many laboratories may not have the capability to perform this test. Only highly-specialized labs with advanced facilities and testing procedures perform this test
  • Additional mutations are still being discovered in many of these tumors. This may further contribute towards tumor diagnosis and treatment. Please consult with your healthcare provider for any information updates

Certain medications that you may be currently taking may influence the outcome of the test. Hence, it is important to inform your healthcare provider of the complete list of medications (including any herbal supplements) you are currently taking. This will help the healthcare provider interpret your test results more accurately and avoid unnecessary chances of a misdiagnosis.

What are some Useful Resources for Additional Information?

The following DoveMed website link is a useful resource for additional information:


Please visit our Laboratory Procedures Center for more physician-approved health information:


References and Information Sources used for the Article:

https://ghr.nlm.nih.gov/primer/testing/genetictesting (accessed on 02/17/2017)

https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5806a1.htm (accessed on 02/17/2017)

http://www.nature.com/gim/journal/v10/n5/full/gim200852a.html (accessed on 02/17/2017)

http://pediatrics.aappublications.org/content/106/6/1494 (accessed on 02/17/2017)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100035/ (accessed on 02/17/2017)

https://www.ncbi.nlm.nih.gov/pubmed/21885404 (accessed on 02/17/2017)

https://www.ncbi.nlm.nih.gov/pubmed/21584898 (accessed on 02/17/2017)

Helpful Peer-Reviewed Medical Articles:

Carrano, A. V., et al. Measurement and purification of human chromosomes by flow cytometry and sorting. Proceedings of the National Academy of Sciences 76, 1382–1384 (1979)

Drets, M. E., & Shaw, M. W. Specific banding patterns of human chromosomes. Proceedings of the National Academy of Sciences 68, 2073–2077 (1971)

Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31–36 (2002)

Parra, I., & Windle, B. High resolution visual mapping of stretched DNA by fluorescent hybridization. Nature Genetics 5, 17–21 (1993) doi:10.1038/ng0993-17

Pinkel, D., et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genetics 20, 207–211 (1998) doi:10.1038/2524

Speicher, M. R., et al. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nature Genetics 12, 368–375 (1996) doi:10.1038/ng0496-368

Errani, C., Zhang, L., Sung, Y. S., Hajdu, M., Singer, S., Maki, R. G., ... & Antonescu, C. R. (2011). A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes, Chromosomes and Cancer, 50(8), 644-653.

Antonescu, C. R., Loarer, F., Mosquera, J. M., Sboner, A., Zhang, L., Chen, C. L., ... & Weinreb, I. (2013). Novel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes, Chromosomes and Cancer, 52(8), 775-784.

Flucke, U., Vogels, R. J., Somerhausen, N. D. S. A., Creytens, D. H., Riedl, R. G., van Gorp, J. M., ... & Suurmeijer, A. J. (2014). Epithelioid Hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases. Diagnostic pathology, 9(1), 131.

Park, M. S., Ravi, V., & Araujo, D. M. (2010). Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Current opinion in oncology, 22(4), 351-355.

Mistry, A. M., Gorden, D. L., Busler, J. F., Coogan, A. C., & Kelly, B. S. (2012). Diagnostic and therapeutic challenges in hepatic epithelioid hemangioendothelioma. Journal of gastrointestinal cancer, 43(4), 521-525.

Errani, C., Vanel, D., Gambarotti, M., Alberghini, M., Picci, P., & Faldini, C. (2012). Vascular bone tumors: a proposal of a classification based on clinicopathological, radiographic and genetic features. Skeletal radiology, 41(12), 1495-1507.

Prochilo, T., Savelli, G., Bertocchi, P., Abeni, C., Rota, L., Rizzi, A., & Zaniboni, A. (2013). Targeting VEGF-VEGFR pathway by sunitinib in peripheral primitive neuroectodermal tumor, paraganglioma and epithelioid hemangioendothelioma: three case reports. Case reports in oncology, 6(1), 90-97.

Woelfel, C., Liehr, T., Weise, A., Langrehr, J., Kotb, W. A., Pacyna-Gengelbach, M., ... & Petersen, I. (2011). Molecular cytogenetic characterization of epithelioid hemangioendothelioma. Cancer genetics, 204(12), 671-676.

Antonescu, C. R., Chen, H. W., Zhang, L., Sung, Y. S., Panicek, D., Agaram, N. P., ... & Fletcher, C. D. (2014). ZFP36‐FOSB fusion defines a subset of epithelioid hemangioma with atypical features. Genes, Chromosomes and Cancer, 53(11), 951-959.

Patel, N. R., Salim, A. A., Sayeed, H., Sarabia, S. F., Hollingsworth, F., Warren, M., ... & Lazar, A. J. (2015). Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1–CAMTA1 fusion variants. Histopathology, 67(5), 699-708.

Reviewed and Approved by a member of the DoveMed Editorial Board
First uploaded: March 2, 2017
Last updated: March 2, 2017